Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A bayesian network meta-analysis

Archives of Dermatology

Volumn 148, Issue 12, 2012, Pages 1403-1410

  Lin, Vincent W ^a   Ringold, Sarah ^a,b   Devine, Emily Beth ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ETANERCEPT; INFLIXIMAB; PLACEBO; USTEKINUMAB;

ADULT; BODY SURFACE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

EID: 84871378386     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.238     Document Type: Review

References (38)

1. National Psoriasis Foundation. About psoriasis: statistics. http://www.psoriasis.org/page.aspx?pid=1004. Accessed January 6, 2012.
2. Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm. 2011;68(9):795-806.
3. Griffiths CE, Strober BE, van de Kerkhof P, et al ACCEPT Study Group. Comparison of ustekinumab and etanercept formoderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
4. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417-428.
5. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219(3):209-218.
6. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1-233, i-iv.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. (Pubitemid 26120810)
8. Spiegelhalter DJ, Best NG, Carlin BP, Van der Linde A. Bayesian measures of model complexity and fit (with discussion). J R Stat Soc B. 2002;64(4):583-616.
9. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10(4):277-303. (Pubitemid 32691157)
10. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24(1):1-19. (Pubitemid 43197227)
11. Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7(4):457-511.
12. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension Study. J Am Acad Dermatol. 2006;55(4):598-606. (Pubitemid 44436647)
13. Asahina A, Nakagawa H, Etoh T, Ohtsuki M; Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299-310.
14. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. (Pubitemid 350298146)
15. Saurat JH, Stingl G, Dubertret L, et al CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. (Pubitemid 351239154)
16. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):12-16.
17. Schlessinger J, Pariser R, Park S, Wierz G. Evaluation of the efficacy and safety of alefacept in patients for whom conventional psoriasis therapies are ineffective or inappropriate [abstract P27221]. J Am Acad Dermalol. 2007;56:AB192.
18. Papp KA, Tyring S, Lahfa M, et al Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304-1312. (Pubitemid 40933433)
19. Leonardi CL, Powers JL, Matheson RT, et al Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014-2022. (Pubitemid 37448924)
20. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29-35. (Pubitemid 43038667)
21. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842-1847. (Pubitemid 32539117)
22. Reich K, Nestle FO, Papp K, et al EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374. (Pubitemid 41443403)
23. Torii H, Nakagawa H; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40-49.
24. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. http://www.jaad.org/article/ S0190-9622(06)02083-4/abstract. Accessed August 22, 2012.
25. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-542. (Pubitemid 39278071)
26. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) [published correction appears in Lancet. 2008;371(9627):1838]. Lancet. 2008;371(9625):1665-1674. (Pubitemid 351671883)
27. Papp KA, Langley RG, Lebwohl M, et al; PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675- 1684. (Pubitemid 351671884)
28. Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther. 2011;5:41-49.
29. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4(suppl 2):S22-S28.
30. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767-774.
31. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-691. (Pubitemid 27341818)
32. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol. 2008;61(5):455-463.
33. Humira [package insert]. North Chicago, IL: Abbott Laboratories; 2011.
34. Amevive [package insert]. Deerfield, IL: Astellas Pharma US Inc; 2011.
35. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corp; 2011.
36. Remicade [package insert]. Horsham, PA: Janssen Biotech Inc; 2011.
37. Stelara [package insert]. Horsham, PA: Centocor Ortho Biotech Inc; 2011.
38. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269-1275. (Pubitemid 43967578)